Valneva Austria Gmbh

This study is carefully watching for side effects in 5,000 people in Brazil who have already received a new vaccine for chikungunya virus. The main goal is to understand how common certain health concerns are after vaccination, including heart issues and joint pain. Researchers w…

This study follows adults for up to 10 years after they received a single dose of an experimental chikungunya vaccine. Researchers want to see how long the vaccine's protective antibodies last and monitor participants for any long-term safety issues. The study includes about 363 …

This study aims to measure how well the VLA1553 vaccine prevents chikungunya virus disease in real-world conditions in Brazil. Researchers will compare about 1,200 people who develop chikungunya-like symptoms, checking if vaccinated individuals are less likely to test positive fo…

This study aimed to test a vaccine designed to protect children from the chikungunya virus, a painful mosquito-borne illness. It planned to enroll at least 3,000 healthy children aged 1 to 11 years to receive either the experimental vaccine or a comparator vaccine. The main goal …

This study aims to understand how many people in selected Brazilian communities already have immunity to the chikungunya virus before a new vaccine is introduced. Researchers will test over 5,300 residents, aged 2 and up, from randomly selected households. The goal is to gather i…